
Mount Sinai
Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care teaching facility acclaimed internationally for excellence in clinical care.
U.S. News & World Report ranks The Mount Sinai Hospital among the top hospitals nationwide. Mount Sinai also ranks in several specialties and is top 10 in three of those: Geriatrics (#3), Cardiology and Heart Surgery (#7), and Gastroenterology (#8).

Mount Sinai Hospital
Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care teaching facility acclaimed internationally for excellence in clinical care.
U.S. News & World Report ranks The Mount Sinai Hospital among the top hospitals nationwide. Mount Sinai also ranks in several specialties and is top 10 in three of those: Geriatrics (#3), Cardiology and Heart Surgery (#7), and Gastroenterology (#8).
Dr Saurabh Mehandru
ASSISTANT PROFESSOR Medicine, Gastroenterology
Mount Sinai Hospital
Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care teaching facility acclaimed internationally for excellence in clinical care.
U.S. News & World Report ranks The Mount Sinai Hospital among the top hospitals nationwide. Mount Sinai also ranks in several specialties and is top 10 in three of those: Geriatrics (#3), Cardiology and Heart Surgery (#7), and Gastroenterology (#8).
Kristin Myers
Vice President, IT, Epic Integration
Mount Sinai Innovation Partners
We facilitate the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships
Dr Lambert Edelmann
BD Director
Mount Sinai Innovation Partners
We facilitate the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships
Mr Alan Belicha
Business Development ManagerMTAnalytics
At MTAnalyics we focus on increasing statistical power to improve the detection of weak association signals between variables. By contrast to data mining, we are using statistical tools that allow us to provide power and p-values in our analysis. In other words, we are specific alike classic statistics and sensitive as data mining.
For clinical trials, we significantly reduce the sample size while keeping the same power. Fundamentally, you will be able to decrease your sample size by 30% while keeping the same p-value, the same statistical power. Obvious main consequences: gain of time, of money, resources etc…
Our work addresses these challenges and aims at providing rationale to design and perform statistical analysis when large amount of data are available. We are not competing with the companies allowing to hire patients faster. We come into play before the design of the trial even started to allow for the design of a trial to include a reduced sample size. We focus in particular on increasing statistical power in order to reduce sample size or improving the detection of weak association between variables by leveraging all available information.
In big data, we provide insights into data sets, predict outcomes, increase the strengths of the models used to explain an outcome based on the analysis of a dataset. Again, the basis of our approach is to improve the detection of weak signals.
Any classical approach is able to detect a strong signal, but when an outcome is not explained (or associated) to one major or a few big variables but by a multiple of weak signals, you need a model to link and find these weak signals, in order to explain a maximum of your outcome.
With our approach, we are able to explain significantly more of the outcome, by reinforcing the models, by finding weak associations hidden in the data sets and missed by the other approaches. In other words, we detect associations that others cannot.
Mr Gary Goldmuntz
co-founder
Nano3D Biosciences, Inc.
Biomedical research is gravitating towards 3D cell culture models and tissue printing. At n3D, we sell kits and services for 3D cell culture. Our core technology is the magnetization of cells, which can then be directed using magnetic forces. In this manner, we can either levitate or bioprint cells. These cultures are faster to assemble than other systems and easier to handle with magnets without losing samples. Check out our products and ourservices for more information on our technology, and how we can help you!
Mr Glauco Souza
President and CSONanotech Plus, LLC
Nanotech Plus, LLC is a consulting firm focused on the commercialization of advanced materials. Our clients include Fortune 500 companies to startups as well as government agencies. Whether you need information ranging from a potential market for a new product to an assessment of a patent portfolio, we can help. In our 5 year history, we have had a diverse group of clients with a diverse set of needs- but we've been able to satisfy them all.
Specialtiesconsulting, marketing patent assessment, due diligence